INTRODUCTION
============

Intraocular pressure (IOP) reduction is currently the only treatment available for decreasing the risk of glaucoma progression \[[@R1]\]. However, glaucoma may continue to progress despite IOP reduction to targeted levels \[[@R2]-[@R4]\]. This indicates that factors other than IOP may play an important role in the pathogenesis of glaucoma. The role of vascular risk factors in glaucoma, particularly ocular perfusion pressure (PP), is being increasingly supported by the literature. PP is defined as the difference between arterial and venous pressure, which, in the eye, by convention equals IOP. Therefore, blood pressure (BP) and IOP are the principal components of ocular PP (PP=BP-IOP), which determines the nutritive delivery of arterial blood to capillary beds. Ocular hemodynamics in young healthy individuals, are autoregulated to maintain constant blood supply to ocular tissues, despite changes in PP \[[@R5]\]. However in glaucoma, there is the hypothesis of a defective autoregulation, resulting in ischemic damage and reperfusion injury \[[@R6]\]. In a case-control study by Gherghel *et al*, lower ocular PP was associated with hemodynamic alterations in progressive glaucoma patients \[[@R7]\]. Interestingly, this association was not found in nonprogressive glaucoma patients or healthy individuals.

FROM PP TO ITS PRINCIPAL COMPONENTS: BP AND IOP
===============================================

In several population-based studies BP and IOP have been reported to be positively associated in both healthy individuals \[[@R8]-[@R11]\] and open-angle glaucoma (OAG) subjects \[[@R12]-[@R17]\]. In some studies this association was found for systolic BP, but not for diastolic BP \[[@R10],[@R11]\]. Also, most studies report a positive association between age and IOP \[[@R8],[@R9],[@R12],[@R13],[@R18],[@R19]\], while a negative association has been reported by few Japanese studies \[[@R11],[@R20]\]. In addition, a positive association has been reported between age and BP \[[@R21],[@R22]\]. Based on the above, one may suggest that age is a confounder in the BP-IOP relationship. However, in most studies the association of BP and IOP remained statistically significant after adjustment for age \[[@R8],[@R9],[@R12]-[@R17]\]. Therefore, it seems that the association of BP with IOP is independent of age. Although evidence may suggest an association between BP and IOP, the magnitude of IOP change associated with BP change is small, on the rate of 0.2-0.4mmHg/10mmHg \[[@R23]\].

Because increased IOP and glaucoma are associated, it may be expected that increased BP and glaucoma are also associated, through the BP-IOP relationship. However, hypertension has not been consistently reported as a risk factor for glaucoma \[[@R12],[@R13],[@R24]-[@R28]\]. An association between hypertension and glaucoma has been initially reported by non population-based studies \[[@R24],[@R25]\]. Later, some population-based studies confirmed this association \[[@R12],[@R13],[@R26]\], while others did not \[[@R27],[@R28]\]. Among studies confirming this association, results were adjusted for IOP in the Rotterdam Study \[[@R13]\] and the Blue Mountains Eye Study \[[@R26]\], while in the Egna-Neumarkt Study they were not \[[@R12]\].

Although, there is enough evidence on the IOP-glaucoma relationship and the BP-IOP relationship, the BP-IOP-glaucoma interrelationship is more complex and remains unclear. In addition, one should consider the role of age in the above interrelationship. In the Baltimore Eye Survey, the association of BP and OAG depended on age \[[@R28]\]. Specifically, young hypertensives were less likely to have OAG compared to non-hypertensives, while older hypertensives were more likely to have OAG compared to non-hypertensives \[[@R28]\]. It is possible that age is a surrogate for duration of hypertension and that autoregulative mechanisms may be compromised after years of exposure to hypertension, and thus may predispose to OAG \[[@R29]\].

THE ROLE OF PP IN GLAUCOMA -- A RISK FACTOR FOR GLAUCOMA PREVALENCE, INCIDENCE AND PROGRESSION
==============================================================================================

Low diastolic PP has been consistently associated with increased glaucoma prevalence in population-based studies. In the Baltimore Eye Survey \[[@R28]\], the Barbados Eye Study \[[@R27]\] and the Rotterdam Study \[[@R30]\] low diastolic PP was a risk factor for glaucoma prevalence. Having findings to the same direction, the Egna-Neumarkt Study \[[@R12]\] and the Proyecto VER \[[@R31]\] found that glaucoma prevalence decreases progressively with increased diastolic PP.

Further to that, low diastolic PP has been associated with increased glaucoma incidence. In the Barbados Eye study, a population-based cohort study of 3222 African origin participants with a follow-up of over 9 years, OAG incidence was 4.4% \[[@R32]\]. Among baseline factors included in the analysis, all lower PPs, meaning systolic, diastolic and mean PP, were associated with an increased risk of OAG incidence. In addition, the Early Manifest Glaucoma Trial (EMGT), a prospective randomized clinical trial (RCT) of 255 Caucasian participants with a median follow-up of 8 years, evaluated risk factors for progression of manifest OAG \[[@R33]\]. Overall progression was 67%, while baseline systolic PP ≤ 125 mm Hg was a risk factor for OAG progression (OR, 1.42; 95% CI, 1.04-1.94).

Although findings from cross-sectional studies and the EMGT are consistent on low PP as risk factor for glaucoma, we need to be cautious when interpreting these results. In all cross-sectional studies reporting low PP as a risk factor for glaucoma prevalence results were not adjusted for IOP-lowering and BP-lowering treatment. In addition, even though results were adjusted for IOP, IOP-lowering and BP-lowering treatment in the incidence report of the Barbados Eye Study and the EMGT, residual confounding may still exist.

PP: A TRICKY VARIABLE WITH REGARDS TO IOP AND BP
================================================

PP can be affected by both its components, meaning IOP and BP. However, among the two "players" we do not know who is really playing the game. It could be only IOP, only BP or a combination of both. Even if we assume the third case which seems more reasonable, we do not know the weight of each variable to PP and whether it is the same for the whole IOP spectrum. For example, the Egna-Neumarkt Study did not find an association between low diastolic PP and increased glaucoma prevalence in normal-tension glaucoma \[[@R12]\]. According to the authors, this may be related to the limited number of cases in the normal-tension glaucoma group. However, this might also be because of different pathogenic mechanisms in normal-tension compared to high-tension glaucoma or simply because PP cannot be very low in normal-tension glaucoma due to low IOP values. This hypothesis may also be supported by the Rotterdam Study results, where PP\<50mmHg was positively associated with high-tension glaucoma, while it was inversely associated with normal-tension glaucoma (OR, 0.25; 95% CI, 0.10-0.63) \[[@R30]\].

Further to that, there are few reports on how IOP and BP fluctuate at different time-points during the 24hour period \[[@R34],[@R35]\] and therefore we do not know the result of IOP and BP fluctuation on PP. In a recent report by Kida T *et al*. PP fluctuation was estimated based on both IOP and BP measurements during the 24-hour period \[[@R35]\]. However, this study involved only healthy eyes, while all measurements were performed in the sitting position. More studies will be needed to determine the effect of IOP and BP fluctuation on PP in glaucoma subjects and in real-life conditions.

In addition, evidence suggests that PP can be influenced by high IOP alone or by IOP-lowering treatment. In the Barbados Eye Study and the EMGT, results were adjusted for IOP, IOP-lowering and BP-lowering treatment \[[@R32],[@R33]\]. However, one may not exclude residual confounding. It is possible that there is a different significance of BP depending on the IOP. In the EMGT subgroup analyses with regards to IOP, systolic BP ≤160 mmHg was associated with progression in patients with baseline IOP \<21 mmHg \[[@R33]\]. However, only systolic PP ≤125mmHg, but not systolic BP ≤160 mm Hg was associated with progression in patients with higher baseline IOP. This suggests that the association was possibly driven by high IOP, leading to lower systolic PP.

Another issue that should be considered in order to determine the role of PP in glaucoma is the effect of BP-lowering treatment. The same level of BP may have a different significance in those treated for hypertension compared to non-hypertensive subjects. In a Thessaloniki Eye Study report involving 232 non-glaucoma subjects examined with the Heidelberg Retina Tomograph, low diastolic PP, low diastolic BP and the use of BP-lowering treatment were significantly associated with increased cupping and decreased rim area only in subjects with decreased diastolic BP (\<90 mm Hg) as a result of antihypertensive treatment \[[@R36]\]. Similarly, in the Rotterdam Study low diastolic PP was associated with increased glaucoma prevalence only in subjects treated for hypertension \[[@R30]\]. The type and duration of BP-lowering treatment may also contribute to glaucoma risk. In the European Glaucoma Prevention Study the use of diuretics was an independent risk factor for OAG incidence (OR, 2.41; 95% CI, 1.12-5.19) \[[@R37]\]. This suggests that the type of BP-lowering treatment may be an additional variable to consider when assessing PP.

CONCLUSION
==========

Evidence from the literature may support an age-independent positive association between BP and IOP. However, there is still controversy on the role of hypertension in glaucoma, while the interrelationship between BP, IOP and glaucoma remains unclear. Understanding PP and its role in glaucoma could provide some insight into how these variables interfere and ultimately increase our knowledge on glaucoma pathogenesis. However, there are several factors which should be considered when interpreting the observed associations related to PP. The apparent complexity of the interaction of PP with other potential risk factors for glaucoma suggests that PP warrants further research and cannot be currently considered in the assessment of an individual patient.

In order to be able to introduce PP in clinical practice, we should first determine and quantify the role of PP in glaucoma risk. This would mostly require RCTs specifically designed to address PP. Such RCTs should include vision and/or structure preservation as end-points and involve long-term follow-up.
